NEWS RELEASES
YEAR
-
CANBRIDGE LIFE SCIENCES RAISES $25 MILLION IN SERIES B ROUND LED BY LAPAM CAPITAL
MAY 23, 2017
-
CANbridge Life Sciences and Amoy Diagnostics announced that they have entered into a strategic partnership to develop a companion diagnostic assay for CANbridge’s lead candidate, CAN008, a fully human Fc fusion protein.
MAY 08, 2017
-
CANBRIDGE LIFE SCIENCES AWARDED “DEAL OF THE YEAR 2016 ”BY CHINA HEALTHCARE INVESTMENT CONFERENCE FOR LICENSE OF CANCER CANDIDATE FROM AVEO
MAR 31, 2017
-
FIRST PATIENT DOSED IN CANBRIDGE’S CAN-008 PHASE I/II TRIAL IN NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME IN TAIWAN First CANbridge Clinical Trial
SEP 26, 2016
-
CANBRIDGE SIGNS AGREEMENT WITH BOEHRINGER INGELHEIM TO MANUFACTURE INHIBITORY ANTIBODY,CAN-017, FOR ESOPHAGEAL SQUAMOUS CELL CANCER
AUG 11, 2016
-
CANBRIDGE’S CAN-008 APPROVED FOR PHASE I/II TRIAL IN NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME IN TAIWAN
JUL 26, 2016
-
CANBRIDGE APPOINTS DR. HUAI ZHONG HU AS VICE PRESIDENT OF PRECLINICAL DEVELOPMENT
JUL 05, 2016
-
CANBRIDGE LIFE SCIENCES LTD. ELECTED TO BE A MEMBER OF PHIRDA
JUN 03, 2016
-
JAMES XUE, FOUNDER AND CEO OF CANBRIDGE, PRESENT AT 2016 BOSTON CEO CONFERENCE
MAY 29, 2016
-
CANBRIDGE SUBMITS INVESTIGATIONAL NEW DRUG APPLICATION TO TAIWAN FOOD AND DRUG ADMINISTRATION FOR CAN-008 PHASE I/II TRIAL IN GLIOBLASTOMA SELECTS WUXI BIOLOGICS TO MANUFACTURE CAN-008 FOR THE CHINA MARKET
APR 07, 2016
